MalinHultcrantzMDPhD

Hematologic Oncology

Physician

Overview of Dr. Hultcrantz

Dr. Malin Hultcrantz is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Karolinska Institute Faculty of Medicine and has been in practice 14 years. She is one of 63 doctors at Memorial Sloan Kettering Cancer Center and one of 8 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Hematology. She has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(662) 262-8946

Education & Training

Karolinska Institute Faculty of MedicineClass of 2006

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2016 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2018 - 2025

Clinical Trials

Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
COMPLETED
PHASE1, PHASE2
Roles: Contact
A Study of Belantamab Mafodotin and Nirogacestat in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment Start of enrollment: 2022 Mar 31
Not yet recruiting
Phase 1
Roles: Contact, Principal Investigator
A Study of Colesevelam for Lenalidomide-Associated Diarrhea Start of enrollment: 2018 Dec 03
COMPLETED
PHASE2
Roles: Contact, Principal Investigator
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment Start of enrollment: 2022 Oct 04
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing.
Carlyn R Tan, Alice X Wang, David Nemirovsky, Andriy Derkach, Tala Shekarkhand
Blood Advances. 2025-03-06
Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States.
Malin Hultcrantz, David Kleinman, Ravi Vij, Fernando Escalante, Michel Delforge
Haematologica. 2025-03-01
Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population-based screening study.
Sæmundur Rögnvaldsson, Alessandro Gasparini, Sigrun Thorsteinsdottir, Ingigerdur Sverrisdottir, Elias Eythorsson
British Journal of Haematology. 2025-03-01

Press Mentions

Multicenter Study of Spanish Patients Provides New Insights on COVID-19 in Multiple MyelomaNovember 11th, 2020
COVID-19 Case Fatality Rate 29 Percent in Multiple Myeloma PatientsAugust 6th, 2020